U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H16N2O3
Molecular Weight 212.2456
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUTETHAL

SMILES

CCCCC1(CC)C(=O)NC(=O)NC1=O

InChI

InChIKey=STDBAQMTJLUMFW-UHFFFAOYSA-N
InChI=1S/C10H16N2O3/c1-3-5-6-10(4-2)7(13)11-9(15)12-8(10)14/h3-6H2,1-2H3,(H2,11,12,13,14,15)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.doctoralia.co.uk/medication/soneryl-10028 | http://www.minclinic.ru/drugs/drugs_eng/S/Soneryl.html

Butethal is a sedative and a hypnotic drug indicated for the treatment of severe intractable insomnia. It acts on receptors in the brain (GABA A receptors) causing the release of the chemical GABA. This chemical inhibits certain areas of the brain resulting in sleepiness. Common side effects are: drowsiness, sedation, unsteadiness, vertigo and inco- ordination. Also, hangover effect, paradoxical excitement, confusion, memory defects and skin rashes. Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Soneryl

Approved Use

Soneryl is indicated for the treatment of insomnia.
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
37.5 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BUTETHAL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
The history of barbiturates a century after their clinical introduction.
2005 Dec
Patents

Sample Use Guides

In Vivo Use Guide
100-200 mg at bedtime
Route of Administration: Oral
In Vitro Use Guide
Butethal enhanced GABA binding to rat brain synaptosomal membranes in a dose-dependent manner with the threshold concentration at 6.25 uM.
Name Type Language
BUTETHAL
MI  
Common Name English
NSC-229336
Code English
BUTETHAL [MI]
Common Name English
BUTOBARBITAL
MART.   WHO-DD  
Common Name English
BUTOBARBITONE
Common Name English
Butobarbital [WHO-DD]
Common Name English
5-BUTYL-5-ETHYLBARBITURIC ACID
Systematic Name English
BUTOBARBITAL [MART.]
Common Name English
Classification Tree Code System Code
WHO-VATC QN05CA03
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
LIVERTOX 132
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
NCI_THESAURUS C67084
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
DEA NO. 2100
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
WHO-ATC N05CA03
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
Code System Code Type Description
DRUG BANK
DB01353
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
PRIMARY
NSC
229336
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
PRIMARY
DRUG CENTRAL
449
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
PRIMARY
NCI_THESAURUS
C87459
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
PRIMARY
ECHA (EC/EINECS)
201-019-9
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
PRIMARY
MERCK INDEX
m2794
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
PRIMARY Merck Index
PUBCHEM
6473
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
PRIMARY
WIKIPEDIA
BUTOBARBITAL
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
PRIMARY
RXCUI
19874
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
PRIMARY RxNorm
FDA UNII
OHZ8QAW6YC
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
PRIMARY
ChEMBL
CHEMBL404422
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
PRIMARY
EVMPD
SUB13135MIG
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
PRIMARY
EPA CompTox
DTXSID70227808
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
PRIMARY
MESH
C027712
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
PRIMARY
CAS
77-28-1
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
PRIMARY
SMS_ID
100000076905
Created by admin on Fri Dec 15 14:59:35 GMT 2023 , Edited by admin on Fri Dec 15 14:59:35 GMT 2023
PRIMARY